|
 The
object of this chapter is to provide the audience with information
that might be helpful for the development of trials designed
to study potential agents
that might be helpful for patients with cancer
anorexia and/or
cachexia. I have been fortunate to have had the opportunity
to work with the North Central Cancer Treatment
Group (NCCTG)
during a period when a series of such clinical trials have
been developed (summarized in the table below):
| NCCTG
Megestrol Acetate Experience with Cancer
|
|---|
Trial
| Patients
|
|---|
| Megestrol
acetate vs. placebo | 133
|
| Megestrol
acetate dose/response | 342
|
| Megestrol
acetate/body composition | 12
|
| Megestrol
acetate vs. placebo in newly diagnosed small cell
lung cancer | 243
|
| Megestrol
acetate vs. dexamethasone vs. fluoxymesterone | 480
|
| Megestrol
acetate vs. dronabinol vs. both | 445+
|
| Total | 1655+
|
|
| NCCTG
Experience with Cancer Anorexia/Cachexia Trials
- Other
|
|---|
Trial
| Patients
|
|---|
| Cyproheptadine
vs. placebo | 295
|
| Pentoxifylline
vs. placebo | 70
|
| Hydrazine
sulfate vs. placebo/colon cancer | 127
|
| Hydrazine
sulfate vs. placebo/lung cancer | 243
|
| Total | 735
|
|
In order
to best teach this subject, I have provided one of the more
recent of these trials along with commentary regarding the
reasons that we developed this protocol in the manner in
which we did. This protocol completed its patient accrual
goals in late 1999.
The entire protocol for this study is available here and
includes audio or written comments.
Users may access the protocol two ways. Click
here to begin reading through the protocol from
the beginning. Alternatively, users may use the links on
the left side of the screen to go directly to a specific
portion of the protocol and hear commentary on that particular
section.
|